EVMN — EVOMMUNE, INC. (Healthcare >> Biotechnology)
EVMN FAQ
What is EVMN's ROE?
EVOMMUNE, INC. reports a Return on Equity (ROE) of -24.95%.
What is EVMN's dividend yield?
EVOMMUNE, INC. offers a dividend yield of 0.00%.
What is EVMN's Deepscope Quality Score?
Deepscope rates EVMN's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy EVMN?
Deepscope's AI Timing Score for EVMN is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does EVMN belong to?
EVOMMUNE, INC. is classified under the Healthcare >> Biotechnology sector on the NYSE exchange.
|
USD 19.92
Price
-0.77
(-3.72%)
Day Change
|
|
|---|
EVMN, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 19.92 |
| PBV / Sector |
2.33 / 4.63
|
| Earning Per Share | -2.13 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
8.68 M
|
| Average 1W Daily Value |
8.00 M
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:37 |
| Symbol | EVMN |
| Name | EVOMMUNE, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE |
| Listed Shares | 36.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 710.64 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1841 Page Mill Road, Palo Alto, CA, United States, 94304
Phone: (925) 247-4481
Website: https://www.evommune.com
Sector: Healthcare >> Biotechnology
Description: Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google